Service 03
Genetic Improvement Master Plan with a focus on diseases
A structured program that sets the company's genetic direction for the next 5, 10 and 15 years. It includes diagnosis, breeding-cycle design, selection criteria, trial structure and ongoing follow-up.
Where disease enters the program
The same cycle, two different decisions
The breeding cycle is well known. What the Master Plan changes is the stage at which disease resistance is measured, and that decides how much a mistake costs.
Horizons
What the plan defines for 5, 10 and 15 years
Targets by horizon, reviewed with the company's technical team.
Structure and first results
- Diagnosis of the program and of the priority diseases by region
- Resistance included in the selection criteria
- Phenotyping routine in place at the stages of the cycle
- Clones in the current portfolio classified by disease
Full cycle with resistance
- Breeding cycle running with phenotyping at each filter
- Breeding population renewed with resistant parents
- Multi-site trials by planting region
Protected portfolio
- Clonal portfolio resistant to the priority diseases
- Client's team running the program independently
- Plan review for the next cycle
What the plan includes
Five components, each with a deliverable
Diagnosis
Genetic material, disease history, planting regions and structure of the current program.
Deliverable: diagnostic reportCycle design
Stages, populations, crosses and duration of each phase of breeding.
Deliverable: cycle flowchartSelection criteria
Weights for growth, wood quality and resistance to each priority disease.
Deliverable: selection indexTrial structure
Where, when and with how many clones to phenotype; field and greenhouse trials.
Deliverable: trial calendarOngoing follow-up
Monitoring of results and course corrections with the client's technical team.
Deliverable: periodic meetings and reviewsWhy a focus on diseases
A program without resistance in the index bets the entire portfolio
In Clonar's trials, for five of the seven pathogens assessed, fewer than 40% of clones are resistant. Without measuring, selection on growth picks susceptible clones in the same proportion.
Source: Clonar resistance trials (technical presentation, 2026). Percentages of all clones assessed per pathogen.
Next step
Where is your company's genetics headed over the next 15 years?
We start with a diagnosis of the current program, together with your breeding team.
or write to comercialclonar@gmail.com